Erythropoietin and Soft Tissue Flap Survival: A Systematic Review
- 27 May 2026
- journal article
- review article
- Published by Wiley in Anz Journal of Surgery
Abstract
Background: Erythropoietin (EPO) has emerging tissue‐protective roles, including anti‐apoptotic, anti‐inflammatory, and pro‐angiogenic effects. In reconstructive surgery, where flap necrosis remains a significant challenge, EPO has been investigated as an agent to enhance flap survival. Currently, no pharmacological agent has consistently improved flap survival, underscoring the need for novel therapeutics. Methods: A systematic review was conducted in accordance with PRISMA guidelines. PubMed, Embase, and CENTRAL databases were searched from inception to September 2025. Eligible studies investigated the effect of EPO on surgical flap survival in animal or human models compared with placebo/no treatment, reporting percentage flap necrosis. Secondary outcomes included perfusion, histological and molecular parameters, and safety. Results: Nine animal studies met the pre‐defined inclusion criteria (mice, n = 139; rats, n = 196) using random‐pattern dorsal, musculocutaneous, and TRAM flap models. All studies evaluated the effect of recombinant human EPO with a variety of different doses, routes, and time applications. Across all studies, EPO was associated with reduced flap necrosis versus controls, with the greatest benefit observed from short‐course, low‐dose peri‐operative regimes. High‐dose or prolonged schedules were less effective and occasionally detrimental. EPO improved perfusion (capillary density, arteriolar flow), enhanced microvascularity and tissue preservation, and upregulated vascular endothelial growth factor (VEGF) and endothelial nitric oxide synthase (NOS) with reduced oxidative stress. No thrombotic events or treatment‐related mortality were reported. Conclusion: EPO improves flap survival in experimental animal models. Short‐term, low‐dose preconditioning appears most effective, while higher doses raise safety concerns. Translation to clinical practice requires optimization of dosing strategies and rigorous clinical trials.Keywords
This publication has 26 references indexed in Scilit:
- Strategies Following Free Flap Failure in Lower Extremity Trauma: A Systematic ReviewJPRAS Open, 2023
- Efficacy of erythropoietin for wound healing: A systematic review of the literatureAnnals of Medicine & Surgery, 2021
- Dual Switch Mechanism of Erythropoietin as an Antiapoptotic and Pro-Angiogenic Determinant in the RetinaACS Omega, 2020
- Erythropoietin and its derivatives: from tissue protection to immune regulationCell Death & Disease, 2020
- Long-term pre- and postconditioning with low doses of erythropoietin protects critically perfused musculocutaneous tissue from necrosisJournal of Plastic, Reconstructive & Aesthetic Surgery, 2019
- Erythropoetin in der Plastischen ChirurgieHandchirurgie · Mikrochirurgie · Plastische Chirurgie, 2013
- The Nonhematopoietic Effects of Erythropoietin in Skin Regeneration and Repair: From Basic Research to Clinical UseMedicinal Research Reviews, 2012
- Erythropoietin-induced upregulation of endothelial nitric oxide synthase but not vascular endothelial growth factor prevents musculocutaneous tissue from ischemic damageLaboratory Investigation, 2010
- Erythropoietin reduces necrosis in critically ischemic myocutaneous tissue by protecting nutritive perfusion in a dose-dependent mannerSurgery, 2009
- Pharmacokinetics of Intraperitoneal, Intravenous, and Subcutaneous Recombinant Human Erythropoietin in Patients on Continuous Ambulatory Peritoneal DialysisAmerican Journal of Kidney Diseases, 1993